Introduction
Fetal somatic gene therapy is, for some reason, often seen as ethically particularly controversial. Unfortunately, many of the adverse reactions to this approach such as accusations of wanting to play god, to manipulate the germ-line, to create designer babies or to tamper with evolution appear to be based on misunderstanding, confusion and sometimes just sheer emotions. However there are, no doubt, some serious questions and concerns in relation to in utero gene therapy, which need to be addressed both from a scientific, as well as from an ethical point of view. Among them are the following frequently asked questions, which we review here:
(1) Should fetal gene therapy be preferred over postnatal gene therapy? (2) Should fetal gene therapy be preferred over preimplantation selection or abortion? (3) What is the scientific background to justify fetal somatic gene therapy? (4) What are the risks of inadvertent germ-line gene transfer? (5) What are the risks to fetus and mother? (6) Does fetal gene therapy infringe the right to abortion? (7) What is the legal status of the fetus and how does fetal gene therapy conform with informed consent?
The hypothesis
Before trying to answer these questions we would like to emphasise that fetal or in utero somatic gene therapy is still an experimental concept for the treatment and hopefully the prevention of genetic disease. It is therefore presently studied exclusively on animal models in order to address the hypotheses on which it is based. These hypotheses are that it may allow targeting of otherwise inaccessible organs or tissues with relatively low vector doses; that it may achieve permanent gene expression by use of integrating vectors in still expanding stem cell populations; and that prenatal tolerance may avoid immune reactions against vector and transgenic protein. 1 If these goals can be achieved, fetal gene therapy may be able to provide prenatal prevention and permanent correction of disease manifestation particularly for early onset diseases.
Successful in utero gene therapy may offer prenatal treatment/prevention as a third option for families faced with prenatal diagnosis of severe genetic disease, where up to now acceptance of an affected child or termination of pregnancy are the only choices. It may thus dramatically change the aims of prenatal screening, which will certainly become a prominent feature of future gene medicine. In fact, it may become the best medical response to the prenatal detection of harmful mutations, which are known to cause early onset severe disease.
Should fetal gene therapy be preferred over postnatal gene therapy?
Obviously, prenatal gene therapy is not to be seen as an alternative to postnatal gene therapy. It would, however, broaden the potential of gene therapy with a clear orientation to early prevention of severe genetic disease. The immediate future application would be for life-threatening monogenic diseases, caused by the absence or inactivation of an essential gene product. The gene defect would have to be confirmed by accurate prenatal diagnosis and expression of the corrective gene would preferably not require fine gene regulation. Initially in utero gene therapy would be particularly relevant for diseases presenting early in life for which no curative postnatal treatment is available and in those that cause irreversible damage to the brain before birth, eg some storage diseases. However, for many less severe conditions, the safety, ease and efficiency of the procedures will finally determine whether prenatal or postnatal application is preferable and which of them for which disease.
Should fetal gene therapy be preferred over pre-implantation selection or abortion?
Provided that it is effective and safe there should be no question that it would be preferable to abortion and certainly much less demanding and expensive than preimplantation selection. It should also be remembered that pre-implantation selection requires prior knowledge of the genetic status of the parents before conception and a lengthy and strenuous procedure before selected embryos can be implanted, while fetal gene therapy could be combined with early pregnancy screening for specific genetic diseases.
What is the scientific background to justify fetal somatic gene therapy?
Effectiveness and safety are certainly the main criteria that will determine if and when fetal gene therapy can be considered as a scientifically sound and ethically acceptable approach to dealing with a genetic condition. This assessment will depend on the development of vector systems, the means of application as tested in animal models and of course on the target disease. (For a review of the different animals models and vector systems used so far by various groups see Ref.
2.)

Animal models
The application of adequate animal models is a scientific and ethical prerequisite to develop procedures and to study safety and efficacy before human application can be considered.
Mice offer the great advantage of ease of maintenance and breeding and the availability of a range of mouse models for human genetic disease. However, their small size and differences in physiology limit their usefulness with respect to procedures applicable in the human fetus.
We have found the sheep fetus particularly well suited for in utero gene delivery, as it is a well-established animal model relevant to human fetal physiology. It has a consistent gestation period of 147 days and provides predominantly singleton pregnancies. It also has a good tolerance to in utero manipulations, has anatomical features allowing interventions which are applicable to the human fetus and shows important similarities to humans in the development of the immune system. In addition, efforts are presently under way to use nuclear transfer technology to generate sheep models of human genetic disease in particular for cystic fibrosis. 3 The need for investigations on primates which have also been used by some investigators, 4-6 but also does not provide disease models before human application, will have to be discussed on the basis of results from the aforementioned models.
Gene Therapy
In mice we have successfully applied vectors coding for marker genes and human factor IX, respectively, by intra-amniotic application to the airways, the gut and the fetal skin. Using intra-vascular delivery into yolk sac vessels we can apply the vector to the general circulation and deliver to several organ systems in particular to the liver. Topical application also allows delivery of the constructs to the muscle and other organs. [7] [8] [9] In the sheep fetus we are using minimally invasive ultrasound-guided procedures, which are applied in human fetal medicine, to deliver the vector to several sites. We have successfully accessed the fetal circulation via the umbilical vein on day 102 of gestation (0.7), 10 while attempts at early gestation (0.3) were not successful. Successful i.p., i.a. and i.m. application was achieved in the first third of pregnancy (David et al in preparation). Delivery to the airways via puncture of the trachea is particularly complicated in the sheep fetus, but has been achieved on day 81 (0.5) and later in gestation.
With regards to expression, we have achieved therapeutic levels of human factor IX by adenovirus-mediated gene delivery to the yolk sack vessels (Waddington et al, submitted) and the amniotic cavity and musculature in the mouse fetus 8, 9 and by intra-umbilical injection in the late gestation of sheep, 10 although only for the relatively short period of about 3 weeks. Significantly lower levels were observed in the early gestation of sheep by i.p., i.a. and i.m. application (David et al, in preparation) .
In summary, judging from the sheep model, which appears to be even more demanding than manipulation on the human fetus, in utero gene delivery is obviously technically possible with reasonable safety, depending on the target site and time of application. For instance intraamniotic delivery carries a relatively low risk even at early gestation, intra-umbilical application is safely possible in late gestation, while intra-tracheal delivery remains a demanding technique that can be performed only within a small time window. This means that factor IX expression to treat haemophilia may be easier to accomplish than the treatment of cystic fibrosis.
Vector systems
The choice of the appropriate vector system is obviously crucial for the success of fetal gene therapy. The problems connected with achieving efficient and prolonged transgene expression are the same in prenatal and postnatal gene therapy, although the choice of promoters and other regulatory sequences and the toxic vector doses may be different. Ideally fetal as well as adult gene therapy would require integrating vector systems that could provide permanent gene expression by infecting stem cells and avoid expression shutdown. However, at this early stage one would perhaps accept application of a transient vector system and repeated postnatal application if it were safe and efficient and would give a marked benefit such as avoidance of early disease manifestation and/or provide immune-tolerance.
We have investigated adenoviral, AAV, retroviral and lentiviral vectors in our animal studies on fetal gene therapy. Adenoviral vectors were used successfully to study the procedures and routes of application for in utero gene application. 8, 10, 11 Adenovirus vectors do not integrate into the host genome at any significant level and would therefore appear not to be a good choice for fetal gene delivery. However, they have the advantage of a very good infection capability for many fetal tissues, in particular the fetal liver and they can be prepared in high titre. The combination of these beneficial aspects with the capability of retro/lenti or AAV vectors for genome integration gives chimaeric adenoviral vectors as a tool to deliver these integrating vectors a very promising perspective.
Because of their immunogenic properties, adenovirus vectors are also good models for investigations on immune reactions against vector and transgene after in utero application and our initial experiments indicate that a significant degree of postnatal tolerance against in utero expressed transgenic protein can be achieved in mice (Waddington, submitted).
Although our main aim in fetal gene therapy is permanent gene delivery and expression, high level transient expression from an adenovirus vector may have its merits, for instance to safeguard against the hazards of birth trauma in haemophilia or to induce tolerance against the therapeutic transgene and vector, thus allowing repeated postnatal gene application.
For permanent gene transfer, the vector will have to integrate into the genome of stem cells and continue to express the transgene in their pedigree populations after birth.
MLV-based retroviral vectors appeared initially as best suited for this purpose. However, only relatively low levels of transduction have been achieved with them so far and we could only achieve retroviral gene transfer in utero by application of retrovirus producer cells. 11 This may be due to the sensitivity of the virus to body fluids 11 and the requirement for dividing cells for infection. Both factors could severely limit the rate at which the unsynchronised dividing stem cells may become infected. It may however also reflect an inherent resistance of stem cells to retroviral infection. High titre preparations of VSVG pseudotyped lentivirus vectors may at least overcome the limitations imposed by cell cycle and viral sensitivity. Long-term transgene expression may however still be lost by promoter shutdown which may require constructs with tissue-specific promoters and other control elements.
AAV vectors have the potential for long-term expression, however it appears that the recombinant virus integrates only to a fairly low percentage and after some considerable delay. This may cause loss of the permanent expression potential in a rapidly expanding fetal cell population after the initial transduction. High titre preparations of this apparently non-toxic vector may increase the percentage of infected stem cells, as well as the number of intracellular AAV genomes, which in turn may increase integration and permanence.
What are the risks of inadvertent germ-line gene transfer?
Fetal somatic gene therapy does not attempt to modify the genetic content of the germ-line, however, inadvertent germ-line gene transfer is a frequently voiced concern in connection with in utero gene therapy. After compartmentalisation of the primordial germ cells (PGCs) in the gonads, which is completed in humans by the 7th week of gestation, it seems unlikely that the transgene would reach these cells by other means than perhaps through the circulation. In this respect, fetal gene therapy would carry the same risk for inadvertent germ-line transmission as postnatal gene therapy and indeed all studies on germ-line transmission of gene therapy vectors administered into non-gonadal tissues in adults or in utero have so far failed to demonstrate transmission into the germ-line. After application of adenovirus vectors to the fetal circulation in sheep, we observed infection of the gonads by PCR but could not detect any gene expression in these organs by immunohistochemistry or RT-PCR. 10 Similarly, Porada et al 12 detected retroviral vector DNA by PCR in the gonads of fetal sheep after intraperitoneal application of retroviral vectors, but no germ-line transmission could be found by PCR analysis of sperm derived from three rams born after breeding of in utero-treated animals.
Obviously, germ-line transmission is a general point to consider in gene therapy and will continue to be studied by several generation breeding experiments in mice and by PCR analysis of sperm from in utero-treated animals. It should however be underlined, that the calculated frequency of naturally occurring endogenous insertional mutations in humans of about one in eight individuals is substantially higher than the suggested upper tolerable limit of one insertion event per 6000 sperm due to a gene delivery protocol. 13 Based on these calculations the FDA has recently decided to allow certain clinical phase 1 trials to go ahead despite incomplete biodistribution data or detection of gonadal presence of the vector. Furthermore, gene therapy is not the only iatrogenic procedure which carries the risk of germ-line modification, but unlike the undirected germ-line damage caused for instance by high-dose chemotherapy, the introduction of a single normal gene sequence can be detected relatively easily over the endogenous mutated variant. However, even if it turns out that germ-line transmission cannot be completely avoided the ethical questions arising should be focused on a benefit/risk analysis and will have to be judged in relation to the spontaneous occurrence of germline mutations and to other therapeutic procedures, which cause germ-line damage.
What are the risks to fetus and mother?
Of course in utero gene delivery does carry some specific risks not encountered in postnatal gene delivery. Similar to most obstetric interventions they concern the mother, as well as the fetus, with a bias for life and well-being clearly in preference of the mother. These risks are infection, fetal loss and preterm labour as a consequence of the intervention.
A more hypothetical risk concerns the possibility that a certain gene product, which is required later in life or a vector system, may be particularly harmful to the fetus or that the insertion of vector sequences into the genome may cause developmental aberrations. These potential risks will be investigated by careful monitoring for any sign of birth defects following in utero manipulation.
However, the main reason that fetal gene therapy, in contrast to adult gene therapy, is not yet at the stage of clinical trials has in our opinion, very little to do with all the perceived dangers of fetal gene therapy per se. This reason is the known inefficiency of almost all present gene therapy approaches, in contrast to a 100% effective preventive alternative, namely abortion! Postnatally this alternative does not exist and therapy of whatever kind seems appropriate is mandatory. In some cases, when it is the last resort and the only alternative to death, it even becomes acceptable in spite of a high risk and low chance of effect. Since termination is a reasonably safe maternal option to deal with an inherited genetic disease, any in utero gene therapy will be expected to be highly reliable in preventing this disease and not causing additional damage. During the introductory phase of transferring this technology to humans, this danger may not be easily ascertained and will require particular care with respect to informed maternal consent based on detailed counselling and the understanding of risks versus benefits. We see this as the main specific ethical issue in fetal gene therapy.
Does fetal gene therapy infringe the right to abortion or the legal status of the fetus and does fetal gene therapy conform with informed consent?
So far we have discussed fetal gene therapy as the opposite to abortion. This is ultimately correct, but will the development of fetal gene therapy negate the right to abortion? This addresses the question of the legal and ethical status of the fetus. In accordance with Fletcher and Richter, 14 we would like to emphasise that the 'pre-viable fetus is totally dependent on a pregnant women's autonomous decision for its status in medicine'. This includes the prospective mother's present right to abortion even of a non-affected fetus, which is already recognised in many societies, as well as the decision to abort an affected fetus or subject it to in utero gene therapy. The availability of fetal gene therapy should not in any way infringe her autonomy in these decisions. On the other hand for those who would only reluctantly have an abortion to avoid postnatal disease or not have an abortion whatever the genetic status of the fetus, the offer of in utero gene therapy for a condition diagnosed during pregnancy would add a new option to decision-making. Following on from this, it is the mother who has to make the decision and who therefore has to be fully informed to be able to give consent.
Presently, fetal somatic gene therapy is still a purely experimental approach using animal models to assess the questions addressed above.
Once proven to be safe and reliable, other considerations such as cost-effectiveness and equal accessibility as well as its relation to genetic screening, and in particular prenatal screening, will have to be addressed. We are fully aware that for this approach to gene therapy to become truly preventive it will require the broad support and ethical acceptance of the majority of the population. This can only be achieved on the basis of intensive experiGene Therapy mental research and in-depth information about its benefits and risks in discussions with health professionals and the lay public.
